Ardelyx Is Doing Everything We Can to Ensure That

Patients Prescribed Our Medicines Can Access Our Medicines

ArdelyxAssist logo

How to prescribe IBSRELA


E-prescribe IBSRELA 50 mg BID to Transition Pharmacy Services (TPS)

ArdelyxAssist will partner with Transition Pharmacy Services (TPS) to conduct a benefits investigation and assist with prior authorization

Upon insurance approval, the patient can decide if they would like home delivery through ArdelyxAssist or if they would like to receive IBSRELA through another pharmacy

computer icon

Alternatively, if you currently work with a specialty pharmacy and would like to send IBSRELA prescriptions directly to that pharmacy, we know that the following pharmacies have experience supporting and filling IBSRELA prescriptions: ahma Rx, ARROW PHARMACY, Blue Sky Specialty Pharmacy, Choice Specialty Pharmacy, J&D Pharmacy, LifeLine Specialty Pharmacy, Link Pharmacy, Parkway Specialty Pharmacy, Perigon Pharmacy 360 LLC, Premier Pharmacy Services, Simplex Pharmacy, Synergen Rx, and Village Pharmacy & Compounding. If there is a specialty pharmacy that you currently work with that is not listed here, please contact us so we can explore if that pharmacy is able to support and fill IBSRELA prescriptions.

This is not necessarily a comprehensive list of all the specialty pharmacies that support and fill IBSRELA prescriptions.

copay card image

ArdelyxAssist offers several programs to support patient affordability


  • Commercially insured patients can pay as little as $0* per prescription through the IBSRELA copay program
  • ArdelyxAssist offers additional programs for eligible patients who are uninsured or underinsured and are unable to afford IBSRELA

ArdelyxAssist is here to help. Call us at 844-427-7352, option 1 if you have any questions or need support with IBSRELA access or affordability.

To fax a prescription: (866) 694-2555

*Terms and conditions apply.
Copay is unavailable to government beneficiaries.

Resources for you and your patients


thumbnail of downloadable resource

Commercial Copay Card
 

Download Copay Card

thumbnail of downloadable resource

Sample Letter of
Medical Necessity

Download Template

Explore IBSRELA

Find more Resources

computer icon

IMPORTANT SAFETY INFORMATION

WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS

IBSRELA is contraindicated in patients less than 6 years of age; in nonclinical studies in young juvenile rats administration of tenapanor caused deaths presumed to be due to dehydration. Avoid use of IBSRELA in patients 6 years to less than 12 years of age. The safety and effectiveness of IBSRELA have not been established in patients less than 18 years of age.

CONTRAINDICATIONS

  • IBSRELA is contraindicated in patients less than 6 years of age due to the risk of serious dehydration.
  • IBSRELA is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.

WARNINGS AND PRECAUTIONS

Risk of Serious Dehydration in Pediatric Patients

  • IBSRELA is contraindicated in patients below 6 years of age. The safety and effectiveness of IBSRELA in patients less than 18 years of age have not been established. In young juvenile rats (less than 1 week old; approximate human age equivalent of less than 2 years of age), decreased body weight and deaths occurred, presumed to be due to dehydration, following oral administration of tenapanor. There are no data available in older juvenile rats (human age equivalent 2 years to less than 12 years).
  • Avoid the use of IBSRELA in patients 6 years to less than 12 years of age. Although there are no data in older juvenile rats, given the deaths in younger rats and the lack of clinical safety and efficacy data in pediatric patients, avoid the use of IBSRELA in patients 6 years to less than 12 years of age.

Diarrhea

Diarrhea was the most common adverse reaction in two randomized, double-blind, placebo-controlled trials of IBS-C. Severe diarrhea was reported in 2.5% of IBSRELA-treated patients. If severe diarrhea occurs, suspend dosing and rehydrate patient.

MOST COMMON ADVERSE REACTIONS

The most common adverse reactions in IBSRELA-treated patients (incidence ≥2% and greater than placebo) were: diarrhea (16% vs 4% placebo), abdominal distension (3% vs <1%), flatulence (3% vs 1%) and dizziness (2% vs <1%).

INDICATION

IBSRELA (tenapanor) is indicated for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in adults.

Please see full Prescribing Information, including Boxed Warning, for additional risk information.